Mepolizumab
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Mepolizumab: From Eosinophilic Diseases to Immune-Mediated Thrombocytopenia
One-Sentence Summary
Currently, detailed mechanism of action data is not available. Based on known information, mepolizumab is an anti-IL-5 monoclonal antibody, part of the eosinophil-targeted biologic class, and its efficacy in eosinophilic diseases (hypereosinophilic syndrome, EGPA, eosinophilic asthma) has been established. The TxGNN model predicts it may be effective for immune-mediated thrombocytopenia, but this is currently supported only by 1 case report and no clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in Taiwan regulatory data (drug not marketed in Taiwan); per available evidence-pack text, approved elsewhere for eosinophilic diseases (HES, EGPA, eosinophilic asthma) |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 99.66% |
| Evidence Level | L4 |
| EU Market Status | Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for mepolizumab is not available in this evidence pack (Data Gap, High severity). Based on known information, mepolizumab is an anti-IL-5 monoclonal antibody that inhibits eosinophil differentiation and survival, and its approved indications center on eosinophil-driven conditions such as hypereosinophilic syndrome (HES), EGPA, and eosinophilic asthma.
The mechanistic rationale for this prediction is indirect: some HES patients present with a secondary, ITP-like immune thrombocytopenia, suggesting that eosinophil-mediated immune dysregulation may contribute to platelet destruction in certain patients. However, IL-5 inhibition has no established direct pharmacological target on platelets or on the immune pathways that mediate platelet destruction — the association is a disease co-occurrence pattern rather than a validated mechanistic link. This is reflected in the single supporting publication, which is a case report of a patient with concomitant hypereosinophilia and thrombotic microangiopathy rather than a study designed to test mepolizumab in immune thrombocytopenia.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28648630 | 2018 | Case Report | Blood Cells, Molecules & Diseases | Single case of steroid-resistant hypereosinophilic immune diathesis (with aHUS-associated thrombotic microangiopathy) treated with mepolizumab, resulting in resolution of hypereosinophilia and concomitant improvement of the thrombotic microangiopathy |
Safety Considerations
Please refer to the SmPC for safety information. Note: TFDA label warnings/contraindications for this drug are currently missing (Blocking data gap) and must be obtained before any safety evaluation can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a single case report (L4 evidence) with an indirect, disease-co-occurrence mechanistic rationale rather than a validated pharmacological link; no clinical trials exist for this indication, and the drug is not currently marketed in Taiwan. Critically, TFDA-level safety data (warnings, contraindications) are entirely missing, which blocks any safety pre-assessment (S1).
To proceed, the following is needed:
- TFDA label PDF (warnings/contraindications) to unblock safety pre-assessment (Blocking gap, DG001)
- Detailed mechanism-of-action data via DrugBank API to properly assess mechanistic plausibility (High gap, DG002)
- Prospective clinical or observational evidence (beyond a single case report) specifically evaluating mepolizumab in immune-mediated thrombocytopenia
- Confirmation of Taiwan/EU regulatory and market status before any development planning
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.